Pinned Tweet
LT position PART 1
Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE
Tech positions: In order
$AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB
Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR
Pharmdca retweeted
Oracle $ORCL announced several AI partnerships and infrastructure updates at Oracle AI World in Las Vegas today.
Here's a breakdown of the major announcements:
- $NVDA: Expanding NVIDIA Vera Rubin Superclusters to multi-gigawatt scale. Vera Rubin NVL72 systems and Vera CPUs are now available on Oracle Cloud.
- $GOOGL: Bringing Google's custom TPU chips to Oracle Cloud starting in 2027, making Oracle the first hyperscaler outside Google to offer them. This includes TPU 8t for training and TPU 8i for inference.
- $CBRS: Partnering with Cerebras to bring high-speed AI inference systems to Oracle Cloud in 2027.
- SambaNova: Adding another specialized AI inference chip option to Oracle's cloud infrastructure.
- OpenAI: Expanding their partnership with four enterprise offerings that integrate ChatGPT and Codex into business workflows, cybersecurity, application development, and small-business operations.
- $SNOW: Bringing Snowflake's AI Data Cloud to Oracle Cloud as a native, first-party service, with customers able to purchase and manage it directly through Oracle.
Pharmdca retweeted
$CBRS Spike to almost $120 intraday…off Oracle partnership news.
🤔
Pharmdca retweeted
$META's $25B stock sale draws 5x demand.
The offering was priced at $625 per share.
More than half the shares were allocated to long-only and existing investors, while the 15 largest allocations accounted for roughly 70% of the deal.
$XBI Hopefully we've put in a bottom. A growing number of stocks are trading in oversold territory, which could set the stage for a rebound.
Pharmdca retweeted
$SOFI TECHNOLOGIES Q3’26 EARNINGS HIGHLIGHTS
🔹 Revenue: $1.4B (Est. $1.25B) 🟢; +44% YoY
🔹 Adj. EPS: $0.18 (Est. $0.16) 🟢; +64% YoY
🔹 Adjusted EBITDA: $469.8M; +70% YoY
🔹 Members: 17.1M; +35% YoY
FY26 Guide:
🔹 Adj. Revenue: ~$5.04B (Est. $4.87B) 🟢
🔹 Adjusted EPS: ~$0.61 (Est. $0.59) 🟢
🔹 Adjusted EBITDA: ~$1.66B
🔹 Adjusted Net Income: ~$840M
🔹 Member Growth: At least +30% YoY
FY27 Guide:
🔹 Adj. Revenue: ~$6.4B (Est. $6B) 🟢
🔹 Adjusted EPS: ~$0.90 (Est. $0.82) 🟢
🔹 Adjusted EBITDA: ~$2.24B
🔹 Adjusted Net Income: ~$1.28B
Segment Net Revenue:
🔹 Lending: $821.3M; +66% YoY
🔹 Financial Services: $525.1M; +25% YoY
🔹 Technology Platform: $87.4M; -24% YoY
Other Q3 Metrics:
🔹 Total Products: 26.7M; +44% YoY
🔹 Fee-Based Revenue: $570.6M
🔹 Net Interest Margin: 6.14%
🔹 Total Deposits: $51.3B
Comments:
🔸 “We are adding more members, who are using more products, and generating more revenue per product to create the most value for our shareholders over the long run.”
🔸 “Our conviction in the opportunity ahead has never been greater.”
Pharmdca retweeted
$NBIS $149’s to almost $162’s. Nice intraday reversal so far..
SEHAJDEEP SINGH ने क्या गाया! 😱 | Sufi Vibes MAGIC! | Sa Re Ga Ma Pa 202... youtu.be/nWNjmpErHAM?is=eRcM… via @YouTube
No words
Musk showing typical X crowd behavior. Pump your companies and bash competitors.
Musk very vocal when discussing companies, he sees as overvalued, strategically weak, or politically aligned against his views, while simultaneously promoting a highly optimistic narrative around his own businesses such as Tesla, SpaceX, xAI, and X.
$NU BUY THE FEAR.
1) Political fear is often temporary BUT Fundamentals are not. Simple. Ignore election headlines but focus on customer growth, lending and profitability.
2) Brazil's banking market remains highly concentrated. $NU has grown to roughly 139 million customers across Brazil, Mexico and being one of the largest digital banking platforms. In fact, company continues to add millions of customers each quarter.
3) After Brazil, Mexico could be seen as the next growth engine. A massive opportunity as company recently expanding its banking infrastructure there.
4) Net income exceeded $1 Billion for the first time, up 49% year-over-year. Return on equity has almost hit 33%.
Conclusion- Company's growth has been during Lula administration so this selloff after his win makes no sense. In fact, it offers a compelling buying opportunity for long term investors.
In the end, do your due diligence as always. My DD tells me to execute and add this panic driven fear as the underlying business keeps executing and that's all what matters for investors like me. Rest is noise.
Be well.
Pharmdca retweeted
$NU Monness, Crespi, Hardt Initiation, Buy, PT $20
The firm told buyers they get to buy into a macro dislocation tied to the Lula/Bolsonaro runoff, and argued that regardless of who wins the Brazilian presidency, this is a roughly 30% ROE franchise trading at about 13x its FY27E EPS of $1.18, which sits 2% above the Street, with its FY28E estimate 5% above the Street. It said credit is seasoning better than the system, that Copom easing helps borrowers more than net interest income, that Mexico now lends as a bank, and that Monzo is off the table.
Pharmdca retweeted
ANTHROPIC IPO REPORTEDLY ON TRACK FOR NOVEMBER
Anthropic is reportedly preparing to file its S-1 registration at 9 a.m. ET Monday, with an IPO potentially taking place November 19–20, according to Fox Business.
Semiconductor stocks moved higher following the report, reflecting improved sentiment toward AI-related equities.
The key takeaway: A successful Anthropic IPO could provide a major test of investor appetite for AI valuations amid growing concerns over infrastructure spending and financing costs.